trending Market Intelligence /marketintelligence/en/news-insights/trending/rg-gl104l20s4kwp2yti3q2 content esgSubNav
In This List

Immune Design reports results from trials on blood, soft tissue cancer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Immune Design reports results from trials on blood, soft tissue cancer

Immune Design Corp. reported results from two clinical studies testing its potential cancer drugs CMB305 and G100.

The company is testing CMB305 as a monotherapy in a study among 25 patients with previously treated soft tissue sarcoma, or STS, expressing the NY-ESO-1 protein.

CMB305 uses a vaccine approach by generating anti-NY-ESO-1 immune response against the specific STSs — tumors that develop from soft tissues such as fat, muscle, nerves or blood vessels.

Immune Design said the patients survived for a median of 23.7 months after the cancer diagnosis or beginning of treatment, also called overall survival. At least 92% of patients' cancer in the study was resistant or had returned after previous rounds of treatment.

The data was favorable compared to the reported survival duration of 12.4 to 13.5 months for already approved therapies.

Immune Design is planning a phase 3 study in midyear 2018 to test CMB305 as a maintenance therapy for synovial sarcoma, a rare type of STS.

In a separate phase 2 study for patients with a certain blood cancer subtype, the company's investigational drug G100 plus radiotherapy worked better in combination with Merck & Co. Inc.'s Keytruda.

The study tested the combination among 26 patients with follicular lymphoma, which involves abnormal production of B-lymphocyte — a type of white blood cell.

The study showed that the combination therapy reduced cancer by a predefined amount, also called objective response rate, among 54% of the patients compared to 15% for patients given G100 plus radiotherapy alone.

Immune Design said the combination therapy also showed an objective response rate of 75% among patients with a high expression of TLR4, a protein that helps activate the immune system.